🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the battle against superbug strains of the pathogen, according to health experts.

An International Health Concern

The sexually transmitted infection are escalating around the world, with estimates suggesting more than 82 million instances each year. Particularly high rates are reported in the African continent and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the face of rising global incidence, escalating drug resistance and the highly restricted treatment choices currently available.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to significant complications, including infertility. Scientists anticipate that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in the same week. This medication, which is employed against urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This approval marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Data and Global Access

Based on data released by a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the existing first-line therapy, which involves a dual-drug approach. The research involved hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the authority to register and commercialise the drug in numerous regions with limited resources.

Medical professionals directly involved have expressed optimism. The availability of a easy-to-administer therapy such as this is described as a "critical tool" for managing the epidemic. This is viewed as vital to alleviate the strain of the illness for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.